Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton?s Tyrosine Kinase

Tichenor, Mark S.; Wiener, John J.M.; Rao, Navin L.; Bacani, Genesis M.; Wei, Jianmei; Deckhut, Charlotte Pooley; Barbay, J. Kent; Kreutter, Kevin D.; Chang, Leon; Clancy, Kathleen W.; Murrey, Heather E.; Wang, Weixue; Ahn, Kay; Huber, Michael; Rex, Elizabeth; Coe, Kevin J.; Wu, Jiejun; Rui, Haopeng; Sepassi, Kia; Gaudiano, Marcello; Bekkers, Mariette; Cornelissen, Ivo; Packman, Kathryn; Seierstad, Mark; Xiouras, Christos; Bembenek, Scott D.; Alexander, Richard; Milligan, Cynthia; Balasubramanian, Sriram; Lebsack, Alec D.; Venable, Jennifer D.; Philippar, Ulrike; Edwards, James P.; Hirst, Gavin

doi:10.1021/acs.jmedchem.2c01026

Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton?s Tyrosine Kinase

Journal Article · 01 October 2022 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.2c01026· OSTI ID:1902355

Tichenor, Mark S.; Wiener, John J.M.; Rao, Navin L.; Bacani, Genesis M.; Wei, Jianmei; Deckhut, Charlotte Pooley; Barbay, J. Kent; Kreutter, Kevin D.; Chang, Leon; Clancy, Kathleen W.; Murrey, Heather E.; Wang, Weixue; Ahn, Kay; Huber, Michael; Rex, Elizabeth; Coe, Kevin J.; Wu, Jiejun; Rui, Haopeng; Sepassi, Kia; Gaudiano, Marcello more »

Research Organization:: Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)

Sponsoring Organization:: DOE - Office Of Science; INDUSTRY

OSTI ID:: 1902355

Journal Information:: J. Med. Chem., Journal Name: J. Med. Chem. Journal Issue: (21) Vol. 65

Country of Publication:: United States

Language:: ENGLISH

References (32)

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia Byrd, John C.; Harrington, Bonnie; O’Brien, Susan New England Journal of Medicine, Vol. 374, Issue 4 https://doi.org/10.1056/NEJMoa1509981	journal	January 2016
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma Zhang, Jing; Lu, Xueying; Li, Jianyong Biomarker Research, Vol. 10, Issue 1 https://doi.org/10.1186/s40364-022-00357-5	journal	April 2022
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo Ponader, Sabine; Chen, Shih-Shih; Buggy, Joseph J. Blood, Vol. 119, Issue 5 https://doi.org/10.1182/blood-2011-10-386417	journal	February 2012
Discovery of a Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase with Oral Anti-Inflammatory Activity Tichenor, Mark S.; Wiener, John J. M.; Rao, Navin L. ACS Medicinal Chemistry Letters, Vol. 12, Issue 5 https://doi.org/10.1021/acsmedchemlett.1c00044	journal	April 2021
Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists Copeland, Robert A. https://doi.org/10.1002/9781118540398	book	March 2013
A Fast and Clean BTK Inhibitor Gabizon, Ronen; London, Nir Journal of Medicinal Chemistry, Vol. 63, Issue 10 https://doi.org/10.1021/acs.jmedchem.0c00597	journal	May 2020
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib Alsadhan, Anfal; Cheung, Jean; Gulrajani, Michael Clinical Cancer Research, Vol. 26, Issue 12 https://doi.org/10.1158/1078-0432.CCR-19-3505	journal	February 2020
Cutting Edge: Constitutive B Cell Receptor Signaling Is Critical for Basal Growth of B Lymphoma Gururajan, Murali; Jennings, C. Darrell; Bondada, Subbarao The Journal of Immunology, Vol. 176, Issue 10 https://doi.org/10.4049/jimmunol.176.10.5715	journal	May 2006
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT Paul, Juliane; Soujon, Maurice; Wengner, Antje M. Cancer Cell, Vol. 31, Issue 1 https://doi.org/10.1016/j.ccell.2016.12.003	journal	January 2017
Tec Kinases Mediate Sustained Calcium Influx via Site-specific Tyrosine Phosphorylation of the Phospholipase Cγ Src Homology 2-Src Homology 3 Linker Humphries, Lisa A.; Dangelmaier, Carol; Sommer, Karen Journal of Biological Chemistry, Vol. 279, Issue 36 https://doi.org/10.1074/jbc.M311985200	journal	June 2004
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann ChemMedChem, Vol. 2, Issue 1 https://doi.org/10.1002/cmdc.200600221	journal	January 2007
Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018) Feng, Yifan; Duan, Weiming; Cu, Xiaochuan Expert Opinion on Therapeutic Patents, Vol. 29, Issue 4 https://doi.org/10.1080/13543776.2019.1594777	journal	March 2019
Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance Sun, Shan-Liang; Wu, Shi-Han; Kang, Ji-Bo Journal of Medicinal Chemistry, Vol. 65, Issue 11 https://doi.org/10.1021/acs.jmedchem.2c00030	journal	May 2022
Discovery of Pteridine-7(8H)-one Derivatives as Potent and Selective Inhibitors of Bruton’s Tyrosine Kinase (BTK) Dou, Dou; Diao, Yanyan; Sha, Wenjie Journal of Medicinal Chemistry, Vol. 65, Issue 3 https://doi.org/10.1021/acs.jmedchem.1c02208	journal	January 2022
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase Angst, Daniela; Gessier, François; Janser, Philipp Journal of Medicinal Chemistry, Vol. 63, Issue 10 https://doi.org/10.1021/acs.jmedchem.9b01916	journal	February 2020
Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption Ariza, Yuko; Murata, Masayuki; Ueda, Yoshiko Bone Reports, Vol. 10 https://doi.org/10.1016/j.bonr.2019.100201	journal	June 2019
Regioselective Derivatizations of a Tribrominated Atropisomeric Benzamide Scaffold Barrett, Kimberly T.; Miller, Scott J. Organic Letters, Vol. 17, Issue 3 https://doi.org/10.1021/ol503593y	journal	January 2015
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Davis, R. Eric; Ngo, Vu N.; Lenz, Georg Nature, Vol. 463, Issue 7277 https://doi.org/10.1038/nature08638	journal	January 2010
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase Guo, Yunhang; Liu, Ye; Hu, Nan Journal of Medicinal Chemistry, Vol. 62, Issue 17 https://doi.org/10.1021/acs.jmedchem.9b00687	journal	August 2019
Second-generation inhibitors of Bruton tyrosine kinase Wu, Jingjing; Liu, Christina; Tsui, Stella T. Journal of Hematology & Oncology, Vol. 9, Issue 1 https://doi.org/10.1186/s13045-016-0313-y	journal	September 2016
Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design Sabat, Mark; Dougan, Douglas R.; Knight, Beverly Journal of Medicinal Chemistry, Vol. 64, Issue 17 https://doi.org/10.1021/acs.jmedchem.1c01026	journal	August 2021
Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints Hsu, Jonathan; Gu, Yajuan; Tan, Seng-Lai Immunology Letters, Vol. 150, Issue 1-2 https://doi.org/10.1016/j.imlet.2012.12.007	journal	February 2013
Targeting Bruton's tyrosine kinase in B cell malignancies Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P. Nature Reviews Cancer, Vol. 14, Issue 4 https://doi.org/10.1038/nrc3702	journal	March 2014
Bruton Tyrosine Kinase Inhibitors Burger, Jan A. The Cancer Journal, Vol. 25, Issue 6 https://doi.org/10.1097/PPO.0000000000000412	journal	November 2019
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study Schafer, Peter H.; Kivitz, Alan J.; Ma, Jianglin Rheumatology and Therapy, Vol. 7, Issue 1 https://doi.org/10.1007/s40744-019-00182-7	journal	November 2019
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng Chemistry & Biology, Vol. 20, Issue 2 https://doi.org/10.1016/j.chembiol.2012.12.006	journal	February 2013
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia Herishanu, Yair; Pérez-Galán, Patricia; Liu, Delong Blood, Vol. 117, Issue 2 https://doi.org/10.1182/blood-2010-05-284984	journal	January 2011
The Src, Syk, and Tec family kinases: Distinct types of molecular switches Bradshaw, J. Michael Cellular Signalling, Vol. 22, Issue 8 https://doi.org/10.1016/j.cellsig.2010.03.001	journal	August 2010
Mechanisms of B-cell lymphoma pathogenesis Küppers, Ralf Nature Reviews Cancer, Vol. 5, Issue 4 https://doi.org/10.1038/nrc1589	journal	April 2005
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective Brullo, Chiara; Villa, Carla; Tasso, Bruno International Journal of Molecular Sciences, Vol. 22, Issue 14 https://doi.org/10.3390/ijms22147641	journal	July 2021
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success Lovering, Frank; Bikker, Jack; Humblet, Christine Journal of Medicinal Chemistry, Vol. 52, Issue 21 https://doi.org/10.1021/jm901241e	journal	November 2009
Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib) Owens, Timothy D.; Brameld, Ken A.; Verner, Erik J. Journal of Medicinal Chemistry, Vol. 65, Issue 7 https://doi.org/10.1021/acs.jmedchem.1c01170	journal	March 2022

Similar Records

Discovery of BIIB068: A Selective, Potent, Reversible Bruton?s Tyrosine Kinase Inhibitor as an Orall

Journal Article · 2020 · J. Med. Chem. · OSTI ID:1833661

Discovery of BIIB068: A Selective, Potent, Reversible Bruton?s Tyrosine Kinase Inhibitor as an Orall

Journal Article · 2020 · J. Med. Chem. · OSTI ID:1836743

Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834

Journal Article · 2015 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1252343

Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton?s Tyrosine Kinase

Citation Formats

References (32)

Similar Records

Related Subjects